TP53 and gastric cancer: Of the 300 specimens of GC being analyzed, the MSI subtype accounts for 23%, MSS/EMT 20%, MSS/TP53+ (mutated) 26%, and MSS/TP53− (wild-type) 36% (Figure 2).